Press release
Hypercholesterolemia Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | EPIC BIO, Amytrx Therapeutics, Chroma Medicine, Verve Therapeutics, Inc, Vaxxinity, Inc, Arrowhead Pharmaceuticals, Merc
"Hypercholesterolemia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypercholesterolemia Market.
The Hypercholesterolemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Hypercholesterolemia Pipeline Report: https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Hypercholesterolemia treatment therapies with a considerable amount of success over the years.
• Hypercholesterolemia companies working in the treatment market are EPIC BIO, Amytrx Therapeutics, Chroma Medicine, Verve Therapeutics, Inc, Vaxxinity, Inc, Arrowhead Pharmaceuticals, Merck Sharp & Dohme LLC, Haisco Pharmaceutical Group Co., Ltd., Akeso Biopharma, Addpharma Inc., Jiangsu HengRui Medicine Co., Ltd., and others, are developing therapies for the Hypercholesterolemia treatment
• Emerging Hypercholesterolemia therapies in the different phases of clinical trials are- EPIC-221, AMTX 100, Research programme: epigenetic editors, VERVE-101, VXX-401, ARO-ANG 3, MK-0616, HSK31679, Ebronucimab, AD-221, SHR-1209, and others are expected to have a significant impact on the Hypercholesterolemia market in the coming years.
• In November 2024, The Dutch late-stage clinical biopharma company, NewAmsterdam, has announced promising topline results from its Phase III TANDEM trial, evaluating the cholesterol-lowering potential of its combination therapy, obicetrapib. This treatment targets individuals with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD).
• In July 2024, NewAmsterdam Pharma has successfully enrolled 407 patients in the pivotal Phase III TANDEM trial, which is evaluating obicetrapib combined with ezetimibe in patients with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD). Obicetrapib has shown excellent tolerability in over 800 patients with elevated lipid levels during NewAmsterdam's clinical trials. As a result, obicetrapib has the potential to become the first cholesteryl ester transfer protein (CETP) inhibitor to reach clinical practice.
Hypercholesterolemia Overview
Hypercholesterolemia is a condition characterized by high levels of cholesterol in the blood. This can lead to the buildup of fatty deposits in the arteries, increasing the risk of heart disease, stroke, and other cardiovascular problems. It is often caused by genetic factors, an unhealthy diet, lack of exercise, or other underlying health conditions.
Get a Free Sample PDF Report to know more about Hypercholesterolemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Hypercholesterolemia Drugs Under Different Phases of Clinical Development Include:
• EPIC-221: EPIC BIO
• AMTX 100: Amytrx Therapeutics
• Research programme: epigenetic editors: Chroma Medicine
• VERVE-101: Verve Therapeutics, Inc
• VXX-401: Vaxxinity, Inc
• ARO-ANG 3: Arrowhead Pharmaceuticals
• MK-0616: Merck Sharp & Dohme LLC
• HSK31679: Haisco Pharmaceutical Group Co., Ltd.
• Ebronucimab: Akeso Biopharma
• AD-221: Addpharma Inc.
• SHR-1209: Jiangsu HengRui Medicine Co., Ltd.
Hypercholesterolemia Pipeline Therapeutics Assessment
• Hypercholesterolemia Assessment by Product Type
• Hypercholesterolemia By Stage and Product Type
• Hypercholesterolemia Assessment by Route of Administration
• Hypercholesterolemia By Stage and Route of Administration
• Hypercholesterolemia Assessment by Molecule Type
• Hypercholesterolemia by Stage and Molecule Type
DelveInsight's Hypercholesterolemia Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Hypercholesterolemia product details are provided in the report. Download the Hypercholesterolemia pipeline report to learn more about the emerging Hypercholesterolemia therapies at:
https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Hypercholesterolemia Therapeutics Market include:
Key companies developing therapies for Hypercholesterolemia are - Regeneron Pharmaceuticals Inc, Verve Therapeutics Inc, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Huons Co Ltd, LipimetiX Development Inc, Novartis AG, Nyrada Inc, Addpharma Inc, and others.
Hypercholesterolemia Pipeline Analysis:
The Hypercholesterolemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hypercholesterolemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypercholesterolemia Treatment.
• Hypercholesterolemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hypercholesterolemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypercholesterolemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Hypercholesterolemia drugs and therapies-
https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Hypercholesterolemia Pipeline Market Drivers
• Increase in prevalence of Hypercholesterolemia, rising number of clinical studies for the treatment of Hypercholesterolemia are some of the important factors that are fueling the Hypercholesterolemia Market.
Hypercholesterolemia Pipeline Market Barriers
• However, high cost associated with the treatment, side effects associated with the disease and other factors are creating obstacles in the Hypercholesterolemia Market growth.
Scope of Hypercholesterolemia Pipeline Drug Insight
• Coverage: Global
• Key Hypercholesterolemia Companies: EPIC BIO, Amytrx Therapeutics, Chroma Medicine, Verve Therapeutics, Inc, Vaxxinity, Inc, Arrowhead Pharmaceuticals, Merck Sharp & Dohme LLC, Haisco Pharmaceutical Group Co., Ltd., Akeso Biopharma, Addpharma Inc., Jiangsu HengRui Medicine Co., Ltd., and others
• Key Hypercholesterolemia Therapies: EPIC-221, AMTX 100, Research programme: epigenetic editors, VERVE-101, VXX-401, ARO-ANG 3, MK-0616, HSK31679, Ebronucimab, AD-221, SHR-1209, and others
• Hypercholesterolemia Therapeutic Assessment: Hypercholesterolemia current marketed and Hypercholesterolemia emerging therapies
• Hypercholesterolemia Market Dynamics: Hypercholesterolemia market drivers and Hypercholesterolemia market barriers
Request for Sample PDF Report for Hypercholesterolemia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Hypercholesterolemia Report Introduction
2. Hypercholesterolemia Executive Summary
3. Hypercholesterolemia Overview
4. Hypercholesterolemia- Analytical Perspective In-depth Commercial Assessment
5. Hypercholesterolemia Pipeline Therapeutics
6. Hypercholesterolemia Late Stage Products (Phase II/III)
7. Hypercholesterolemia Mid Stage Products (Phase II)
8. Hypercholesterolemia Early Stage Products (Phase I)
9. Hypercholesterolemia Preclinical Stage Products
10. Hypercholesterolemia Therapeutics Assessment
11. Hypercholesterolemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hypercholesterolemia Key Companies
14. Hypercholesterolemia Key Products
15. Hypercholesterolemia Unmet Needs
16 . Hypercholesterolemia Market Drivers and Barriers
17. Hypercholesterolemia Future Perspectives and Conclusion
18. Hypercholesterolemia Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Hypercholesterolemia Market https://www.delveinsight.com/report-store/hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Latest Reports:
• Tendinitis Market: https://www.delveinsight.com/report-store/tendonitis-market
• Vascular Closure Devices Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Hydrocephalus Market: https://www.delveinsight.com/report-store/hydrocephalus-market
• Hemophilia A Market: https://www.delveinsight.com/report-store/hemophilia-a2030-market
• Herpes Simplex Virus Market: https://www.delveinsight.com/report-store/genital-herpes-market
• Peripheral Nerve Injuries Market: https://www.delveinsight.com/infographics/peripheral-nerve-injuries-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypercholesterolemia Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | EPIC BIO, Amytrx Therapeutics, Chroma Medicine, Verve Therapeutics, Inc, Vaxxinity, Inc, Arrowhead Pharmaceuticals, Merc here
News-ID: 3783664 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Hypercholesterolemia
Hypercholesterolemia Treatment Market Reviews Analysis Report 2024
Hypercholesterolemia Treatment Market to reach over USD 36.37 billion by the year 2031 - Exclusive Report by InsightAce Analytic
According to a new report by InsightAce Analytic, the "Hypercholesterolemia Treatment Market" in terms of revenue was estimated to be worth $27.9 billion in 2023 and is poised to reach $36.37 billion by 2031, growing at a CAGR of 3.43% from 2024 to 2031.
Get a free Sample copy of the…
Hypercholesterolemia Treatment Market: Transforming Lives: Impact of Hypercholes …
Newark, New Castle, USA: The "Hypercholesterolemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hypercholesterolemia Treatment Market: https://www.growthplusreports.com/report/hypercholesterolemia-treatment-market/8571
This latest report researches the industry structure, sales, revenue,…
Hypercholesterolemia Treatment Market Insights, Forecast to 2031
The report extensively examines the global Hypercholesterolemia Treatment market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Hypercholesterolemia Treatment . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market…
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature…
Hypercholesterolemia Market Global Analysis & 2023 Forecast Report
Increased level of total cholesterol and LDL (bad) cholesterol in the blood leads to hypercholesterolemia. The normal biological range of total blood cholesterol is 140-200 mg/dL. Hypercholesterolemia leads to cardiovascular diseases such as atherosclerosis, stroke etc. Human blood cholesterol mainly consists of High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol. HDL cholesterol is termed as good cholesterol for the body. High level of HDL cholesterol…
Hypercholesterolemia Market By Key Trends and Analysis 2023
Increased level of total cholesterol and LDL (bad) cholesterol in the blood leads to hypercholesterolemia. The normal biological range of total blood cholesterol is 140-200 mg/dL. Hypercholesterolemia leads to cardiovascular diseases such as atherosclerosis, stroke etc. Human blood cholesterol mainly consists of High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol. HDL cholesterol is termed as good cholesterol for the body. High level of HDL cholesterol…
